PepGen(US:PEPG) GlobeNewswire News Roomยท2025-06-11 16:00Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against PepGen Inc. due to allegations of violations of federal securities laws related to misleading statements about the effectiveness and safety of its drug PGN-EDO51 and the CONNECT2 study [3][5]. Group 1: Allegations and Legal Actions - The complaint alleges that PepGen and its executives made false statements regarding the effectiveness and safety of PGN-EDO51, leading to an overstatement of its clinical and commercial prospects [5]. - Investors who suffered losses exceeding $50,000 in PepGen between March 7, 2024, and March 3, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][3]. - There is an August 11, 2025, deadline for investors to seek the role of lead plaintiff in the federal securities class action against PepGen [3]. Group 2: Clinical Study Results and Stock Performance - On July 30, 2024, PepGen reported "positive clinical data" from the CONNECT1 study, but analysts noted that the results were below expectations, leading to a 32.69% drop in stock price [6][7]. - A clinical hold notice from the FDA on December 16, 2024, raised concerns about the CONNECT2 study, resulting in a 3.63% decline in stock price [8][9]. - Following updates on safety concerns and a temporary pause of the CONNECT2 study on March 4, 2025, PepGen's stock fell by 18.86% [10][11]. - On May 28, 2025, PepGen announced the discontinuation of its DMD programs after PGN-EDO51 failed to achieve target dystrophin levels [12].